Related Experiment Video
Updated: Dec 10, 2025

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome
Franck Boccara1,2, Murielle Mary-Krause3, Valérie Potard3
1Department of Cardiology Faculty of Medicine AP-HP Hôpitaux de l'Est Parisien Hôpital Saint-Antoine Sorbonne Université Paris France.
Insights
People living with HIV (PLHIV) and HIV-uninfected patients had similar long-term risks after acute coronary syndrome (ACS). However, PLHIV experienced more frequent ACS recurrence, highlighting a critical area for cardiovascular care improvement.
Area of Science:
- Cardiology
- Infectious Diseases
- Public Health
Background:
- Long-term prognosis after acute coronary syndrome (ACS) in people living with HIV (PLHIV) remains unclear.
- Understanding cardiovascular outcomes in PLHIV is crucial for effective disease management and prevention strategies.
Purpose of the Study:
- To compare major adverse cardiac and cerebrovascular events (MACCE) after a first ACS between PLHIV and HIV-uninfected (HIV-) patients.
- To identify determinants of cardiovascular prognosis in these populations.
Main Methods:
- A cohort study enrolled consecutive PLHIV and matched HIV- patients experiencing their first ACS across 23 coronary intensive care units in France.
- Patients were matched for age, sex, and ACS type.
- The primary endpoint was MACCE (cardiac death, recurrent ACS, recurrent coronary revascularization, stroke) assessed at 36-month follow-up.
Main Results:
- No statistically significant difference in overall MACCE risk was observed between PLHIV (17.8%) and HIV- patients (15.1%) at 36 months (P=0.22).
- Recurrent ACS was significantly more frequent among PLHIV (multivariable HR, 6.31; P=0.02), with HIV infection identified as the sole independent predictor.
- PLHIV were less likely to quit smoking (47% vs. 75%; P=0.01) and showed smaller decreases in total cholesterol (-22.3 vs. -35.0 mg/dL; P=0.04).
Conclusions:
- While overall long-term cardiovascular event risk was similar, PLHIV face a higher risk of recurrent ACS after an initial event.
- HIV infection is an independent predictor of ACS recurrence.
- Differences in lifestyle factors (smoking cessation) and lipid management may contribute to disparities in cardiovascular outcomes.
Abstract:
Background It is unclear whether HIV infection affects the long-term prognosis after an acute coronary syndrome (ACS). The objective of the current study was to compare rates of major adverse cardiac and cerebrovascular events after a first ACS between people living with HIV (PLHIV) and HIV-uninfected (HIV-) patients, and to identify determinants of cardiovascular prognosis. Methods and Results Consecutive PLHIV and matched HIV- patients with a first episode of ACS were enrolled in 23 coronary intensive care units in France. Patients were matched for age, sex, and ACS type. The primary end point was major adverse cardiac and cerebrovascular events (cardiac death, recurrent ACS, recurrent coronary revascularization, and stroke) at 36-month follow-up. A total of 103 PLHIV and 195 HIV- patients (mean age, 49 years [SD, 9 years]; 94.0% men) were included. After a mean of 36.6 months (SD, 6.1 months) of follow-up, the risk of major adverse cardiac and cerebrovascular events was not statistically significant between PLHIV and HIV- patients (17.8% and 15.1%, P=0.22; multivariable hazard ratio [HR], 1.60; 95% CI, 0.67-3.82 [P=0.29]). Recurrence of ACS was more frequent among PLHIV (multivariable HR, 6.31; 95% CI, 1.32-30.21 [P=0.02]). Stratified multivariable Cox models showed that HIV infection was the only independent predictor for ACS recurrence. PLHIV were less likely to stop smoking (47% versus 75%; P=0.01) and had smaller total cholesterol decreases (-22.3 versus -35.0 mg/dL; P=0.04). Conclusions Although the overall risk of major adverse cardiac and cerebrovascular events was not statistically significant between PLHIV and HIV- individuals, PLHIV had a higher rate of recurrent ACS. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT00139958.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome I: Introduction
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease III: Clinical Manifestations

